FDA Rejects MDMA for Mental Health Treatment After Identifying Flawed Study Data
CCHR welcomes the FDA’s decision to disapprove the hallucinogenic drug, MDMA (Ecstasy) saying if approved, it would have fueled a planned $12 billion industry to…
Tag Archives: MDMA
FDA Panel Overwhelmingly Rejects MDMA Psychedelic as Mental Health Treatment
CCHR applauds the panel’s decision amid concerns over biased clinical trials and risks such as heart attacks, strokes, psychosis, and sexual abuse of patients during…
CCHR Cautions Legislators as FDA Weighs Approval of Psychedelics Amid Rising Violence
Mental health watchdog says adding psychedelics as approved mental health treatment will fuel more acts of drug-induced violence in the community. By Jan EastgatePresident, CCHR…
Aussie psychiatrists McGorry and Hickie—More Brave New World Tricks—Tripping Out Autistic Young Adults with Psychedelics
MDMA and psilocybin psychiatric research is a bad “trip” for mental health in Australia, U.S. and globally. By CCHR International The Mental Health Industry Watchdog…
Piling one failure on top of another, chasing what they see as a multi-billion-dollar jackpot, psychiatrists and the hallucinogenic drug industry are seeking to replace failed antidepressants with earlier banned hallucinogenics
Consumers and investors beware: “Bad ideas don’t get better with time.” By CCHR International The Mental Health Industry Watchdog November 8, 2021 The Citizens Commission…